



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



LAU-0901

Item No. 38414

CAS Registry No.: 727358-25-0
Formal Name: 1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid, 3-[2-(3,4-dichlorophenoxy)ethyl] 5-[2-(4-morpholinyl)-1-(4-morpholinylmethyl)ethyl] ester

MF: C₂₉H₃₉Cl₂N₃O₇


FW: 612.5

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LAU-0901 is supplied as a solid. A stock solution may be made by dissolving the LAU-0901 in the solvent of choice, which should be purged with an inert gas. LAU-0901 is soluble in DMSO.

Description

LAU-0901 is a platelet-activating factor (PAF) receptor antagonist.^{1,2} *In vivo*, LAU-0901 (30, 60, and 90 mg/kg) reduces infarct volume and improves neurological function in a rat model of cerebral ischemia induced by middle cerebral artery occlusion (MCAO).¹ It also reduces microglial infiltration and increases astrocytic and neuronal survival in the same model.² LAU-0901 (30 mg/kg) alone, or in combination with atorvastatin (Item No. 10453), reduces tumor growth in a U87MG glioblastoma mouse orthotopic tumor model.³

References

1. Belayev, L., Khoutorova, L., Atkins, K., *et al.* LAU-0901, a novel platelet-activating factor antagonist, is highly neuroprotective in cerebral ischemia. *Exp. Neurol.* **214**(2), 253-258 (2008).
2. Belayev, L., Eady, T.N., Khoutorova, L., *et al.* Superior neuroprotective efficacy of LAU-0901, a novel platelet-activating factor antagonist, in experimental stroke. *Transl. Stroke Res.* **3**(1), 154-163 (2012).
3. Cruz Flores, V.A., Menghani, H., Mukherjee, P.K., *et al.* Combined therapy with avastin, a PAF receptor antagonist and a lipid mediator inhibited glioblastoma tumor growth. *Front. Pharmacol.* **12**, 746470 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/30/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM